Evidence map›Paper›PMID 29142956›Full record

ArticleKidney international reports2017

Hypertension Control, Apparent Treatment Resistance, and Outcomes in the Elderly Population With Chronic Kidney Disease.

Jean Kaboré, Marie Metzger, Catherine Helmer, Claudine Berr, Christophe Tzourio, Tilman B Drueke, Ziad A Massy, Bénédicte Stengel

Open access · goldAbstract read
In one paragraph

Article in Kidney international reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Jean KaboréCESP, Inserm UMR1018 Team 5, University of Paris-Sud, UVSQ, University Paris-Saclay, Villejuif, France.
Marie MetzgerCESP, Inserm UMR1018 Team 5, University of Paris-Sud, UVSQ, University Paris-Saclay, Villejuif, France.
Catherine HelmerInserm, UMR1219 Population Health, Bordeaux, France.
Claudine BerrInserm U1061, Montpellier, France.
Christophe TzourioInserm, UMR1219 Population Health, Bordeaux, France.
Tilman B DruekeCESP, Inserm UMR1018 Team 5, University of Paris-Sud, UVSQ, University Paris-Saclay, Villejuif, France.
Ziad A MassyCESP, Inserm UMR1018 Team 5, University of Paris-Sud, UVSQ, University Paris-Saclay, Villejuif, France.
Bénédicte StengelCESP, Inserm UMR1018 Team 5, University of Paris-Sud, UVSQ, University Paris-Saclay, Villejuif, France.
Inserm · FRUniversité Paris-Sud · FRUniversité de Bordeaux · FRUniversité de Versailles Saint-Quentin-en-Yvelines · FRUniversité Paris-Saclay · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionChronic kidney disease (CKD) is often associated with poor hypertension control and treatment resistance, but whether CKD modifies the effect of hypertension control on outcomes is unknown.

methodsWe studied 10-year mortality and cardiovascular events according to hypertension control status and CKD (glomerular filtration rate <60 ml/min/1.73m

resultsAt baseline, 19% had CKD, and 31.2% had controlled hypertension on ≤3 antihypertensive drugs, 62.3% uncontrolled hypertension ≥140/90 mm Hg on ≤2 drugs, and 6.5% apparent treatment-resistant hypertension (aTRH) ≥140/90 mm Hg with ≥3 drugs or use of ≥4 drugs regardless of level. There were 1115 deaths (305 total cardiovascular deaths) and 274 incident nonfatal or fatal strokes or coronary events. Compared to the reference group (controlled hypertension and no CKD), participants without CKD and with uncontrolled hypertension or aTRH had adjusted hazard ratios for all-cause mortality of 0.86 (0.74-1.01) and 1.09 (0.82-1.46), and those with CKD and controlled or uncontrolled hypertension, or aTRH, of 1.33 (1.06-1.68), 1.14 (0.93-1.39), and 1.34 (0.98-1.85), respectively. Participants with aTRH and CKD had a risk of coronary death more than 3 times higher than that of the reference group; participants with aTHR, with or without CKD, had a risk of stroke more than twice as high, and those with CKD but controlled hypertension a 2 times higher risk for cardiovascular deaths from other causes. DISCUSSION: CKD does not appear to amplify the risk of stroke and coronary events associated with aTRH in this older population. The reasons for excess cardiovascular mortality from other causes associated with controlled hypertension require further study.

Indexed as

cardiovascularchronic kidney diseasehypertension

Identifiers

PMID29142956
PMCPMC5678838
OpenAlexW2548868866

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.